• Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • June 17, 2019
  • Author: EURETINA Brief

Alkahest’s oral small molecule drug aims to report on a Phase IIa study for age-related macular degeneration

Alkahest Inc., a clinical stage biopharmaceutical company based in San Carlos, California, has announced that an experimental drug, AKST4290, in a Phase IIa study for AMD, showed that  83% of patients maintained or improved their visual acuity, and 21% of patients gained at least 15 letters in BCVA. The open-label Hungarian trial enrolled 29 patients to receive twice-daily 400 mg oral AKST4290 and, to date, results reported an mean improvement of 7 letters in best corrected visual acuity (BCVA) from a baseline to six weeks in treatment-naïve patients.

 

The clinical trial states that the AKST4290 molecule will evaluate the therapeutic effects and safety of 800 mg administered daily over a 6-week dosing period in newly diagnosed patients with wet age-related macular degeneration (wAMD).  The NCT identifier, NCT03558061, is logged in clinicaltrials.gov and a study report should be available within 12-months from the completion of the trial.  Similarly, the European Union Clinical Trials Register (EUCTR) will also report the results of the trial should be available also within 12-months of study completion.  According to the company, AKST4290 is a highly selective and potent small molecule antagonist of CCR3 stating the drug as “an orally administered CCR3 inhibitor that blocks the action of eotaxin, an immunomodulatory protein that increases as humans age and with specific age-related diseases. By targeting eotaxin and its downstream effects, AKST4290 may reduce the hallmark inflammation and neovascularization of wet AMD while also acting more broadly to reduce inflammation associated with many other age-related diseases”.

 

Commenting on the clinical trial results, Dr. Michael Stewart, Chair, Department of Ophthalmology at the Mayo Clinic, Jacksonville stated: “These early data for AKST4290 are extremely promising, showing an impressive increase in visual acuity even over a short 6-week period of treatment. The potential for gaining meaningful visual improvement with an oral agent in neovascular AMD represents a major step forward for patients. Based on the data, it is clear these encouraging results warrant further study.”

PrevPrevious
NextNext

You might also like

EURETINA Hamburg 2022 Keynote Speakers

Read More

EURETINA Educational Webinar: Diabetes and Vascular Diseases (23 Jun, 2022)

Read More

Apellis International: The Future of Geographic Atrophy: advancing diagnosis, treatment and management

Read More

Meet the Keynote Speakers

Keynote Speaker - Sobha Sivaprasad
Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login